M
436.11
-1.74 (-0.40%)
| Previous Close | 437.85 |
| Open | 435.25 |
| Volume | 425,099 |
| Avg. Volume (3M) | 376,167 |
| Market Cap | 9,720,455,168 |
| Price / Sales | 18.75 |
| Price / Book | 14.07 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -123.38% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -17.83 |
| Total Debt/Equity (MRQ) | 16.85% |
| Current Ratio (MRQ) | 5.91 |
| Operating Cash Flow (TTM) | -395.31 M |
| Levered Free Cash Flow (TTM) | -274.11 M |
| Return on Assets (TTM) | -25.56% |
| Return on Equity (TTM) | -50.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.73% |
| % Held by Institutions | 108.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 554.00 (TD Cowen, 27.03%) | Buy |
| Median | 523.00 (19.92%) | |
| Low | 485.00 (JMP Securities, 11.21%) | Buy |
| Average | 517.60 (18.69%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 407.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 12 Sep 2025 | 526.00 (20.61%) | Buy | 432.22 |
| 06 Aug 2025 | 428.00 (-1.86%) | Buy | 338.11 | |
| HC Wainwright & Co. | 04 Sep 2025 | 500.00 (14.65%) | Buy | 431.21 |
| TD Cowen | 26 Aug 2025 | 554.00 (27.03%) | Buy | 424.86 |
| JMP Securities | 20 Aug 2025 | 485.00 (11.21%) | Buy | 391.66 |
| UBS | 12 Aug 2025 | 523.00 (19.92%) | Buy | 359.00 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SIBOLD WILLIAM JOHN | - | 448.73 | -7,279 | -3,266,306 |
| Aggregate Net Quantity | -7,279 | |||
| Aggregate Net Value ($) | -3,266,306 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 448.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SIBOLD WILLIAM JOHN | Officer | 09 Sep 2025 | Sell (-) | 7,279 | 448.73 | 3,266,306 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |